Ab­b­Vie's pso­ri­a­sis drug Skyrizi beats out Am­gen's block­buster in PhIV head-to-head study

Ab­b­Vie’s pso­ri­a­sis drug Skyrizi beat out Am­gen’s Ote­zla in a Phase IV head-to-head ef­fi­ca­cy and safe­ty study test­ing both treat­ments in adult pa­tients with mod­er­ate plaque pso­ri­a­sis.

Ab­b­Vie said Wednes­day that the IL-23 in­hibitor hit all pri­ma­ry and sec­ondary end­points: At week 16, 55.9% of pa­tients get­ting sub­cu­ta­neous in­jec­tions of Skyrizi saw a 90% or more im­prove­ment from their base­line score on the Pso­ri­a­sis Area and Sever­i­ty In­dex (PASI). In com­par­i­son, 5.1% hit a PASI 90 score in the Ote­zla arm, earn­ing a p-val­ue of <0.001. Ote­zla is an oral treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER